MapLight Therapeutics to Participate in Upcoming Investor Conference
Get Alerts MPLT Hot Sheet
Join SI Premium – FREE
SAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference:
Event: Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY)
Date: Monday, September 14th
Format: Presenting and hosting 1x1 meetings
Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events & Presentations” page on the Investor section of the company’s website at https://ir.maplightrx.com/news-events/events-presentations.
About MapLight Therapeutics
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. For more information, please visit www.maplightrx.com.
For investor inquiries: [email protected]
For media inquiries: [email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- From China Trials to Abu Dhabi: FREELANDER 8 Builds Momentum for Global Brand Launch
- American Fusion Inc. Featured in AGORACOM Interview on Texatron™ and the Race to Power Artificial Intelligence
- Is DigiTap Legit? Its Ethereum Contract Is Public, Supply Is Capped at 2B and Team Tokens Are Locked 5 Years
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share